C4 Therapeutics, Inc. Restructuring and Related Cost, Expected Number of Positions Eliminated
C4 Therapeutics, Inc. (CCCC) reported Restructuring and Related Cost, Expected Number of Positions Eliminated of 45 position for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated · last filed 2024-05-08
- C4 Therapeutics, Inc. restructuring and related cost, expected number of positions eliminated for the quarter ending 2024-03-31 was 45.00 position.
| Period end | Restructuring and Related Cost, Expected Number of Positions Eliminated 3 month |
|---|---|
| 2024-03-31 | 45.00 position 10-Q · filed 2024-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |